First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.

Title
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 15_suppl, Pages 4097-4097
Publisher
American Society of Clinical Oncology (ASCO)
Online
2018-09-05
DOI
10.1200/jco.2018.36.15_suppl.4097

Ask authors/readers for more resources

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started